Expanding the applicability of its marquee
product for the interventional treatment of coronary artery disease in the
United States, Medtronic, Inc. MDT announced today that the U.S. Food
and Drug Administration (FDA) has approved the 34mm and 38mm lengths of the
Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm
with an indication for patients with diabetes.
Now available to cardiac catheterization laboratories nationwide, these new
sizes of the Resolute Integrity stent enable the treatment of long coronary
lesions, which are generally considered to span more than 27mm.
Like the core sizes approved by the FDA in February 2012, the 34mm and 38mm
lengths of the Resolute Integrity stent are uniquely indicated for treating
the coronary artery disease of patients with diabetes, who commonly present
with long lesions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in